C3a Receptor Agonist |
Catalog No.GC43083
One-Click Copy Product Info
|
C3a Receptor Agonist est un agoniste sélectif et spécifique du récepteur du complément 3a (C3aR).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 944997-60-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
C3a Receptor Agonist est un agoniste sélectif et spécifique du récepteur du complément 3a (C3aR)[1]. C3aR est un récepteur couplé aux protéines G principalement exprimé sur les cellules immunitaires (telles que les monocytes, les macrophages et les cellles dendritiques) et les cellules non immunitaires (tells que les cellules endothéliale et les neurones) [2]. Après son activation, C3aR peut médier la transduction du signal en aval, incluant la phosphorylation d' ERK1/2 et la mobilisation des ions calcium intracellulaires, déclenchant ainsi une série d'effets biologiques tels que la chimiotactisme cellulaire, la libération de facteurs inflammatoires, l'adhésion cellulaire et l'augmentation de la perméabilité vasculaire[3]. C3a Receptor Agonist peut être utilisé dans la recherche sur les mécanisme des maladies liées au système du complément.
References:
[1] Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65(1):500-543.
[2] Kim BJ, Mastellos DC, Li Y, Dunaief JL, Lambris JD. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Prog Retin Eye Res. 2021;83:100936.
[3] Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Köhl J. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46(14):2753-2766.
| Cas No. | 944997-60-8 | SDF | |
| Chemical Name | α-cyclohexyl-N-[1-[1-oxo-3-(3-pyridinyl)propyl]-4-piperidinyl]-benzeneacetamide | ||
| Canonical SMILES | O=C(N1CCC(NC(C(C2CCCCC2)C3=CC=CC=C3)=O)CC1)CCC4=CC=CN=C4 | ||
| Formula | C27H35N3O2 | M.Wt | 433.6 |
| Solubility | 30mg/mL in ethanol, 30mg/mL in DMSO, 30mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3063 mL | 11.5314 mL | 23.0627 mL |
| 5 mM | 461.3 μL | 2.3063 mL | 4.6125 mL |
| 10 mM | 230.6 μL | 1.1531 mL | 2.3063 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)